Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. (Q40476927)

20 September 2017

Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. (English)

1 reference

20 September 2017

1 reference

1 reference

Kent R Van Kampen

1

1 reference

20 September 2017

Zhongkai Shi

2

1 reference

20 September 2017

Peng Gao

3

1 reference

20 September 2017

Jianfeng Zhang

4

1 reference

20 September 2017

K Wade Foster

5

1 reference

20 September 2017

Dung-Tsa Chen

6

1 reference

20 September 2017

Donald Marks

7

1 reference

20 September 2017

Craig A Elmets

8

1 reference

20 September 2017

De-chu C Tang

9

1 reference

20 September 2017

language of work or name

English

0 references

publication date

1 January 2005

1 reference

20 September 2017

8

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

20 September 2017

23

1 reference

20 September 2017

1029-1036

1 reference

20 September 2017

8

1 reference

Realities and enigmas of human viral influenza: pathogenesis, epidemiology and control

20 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.043

Eight-plasmid system for rapid generation of influenza virus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.043

Preparation of vaccines against H5N1 influenza.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.043

Egg fluids and cells of the chorioallantoic membrane of embryonated chicken eggs can select different variants of influenza A (H3N2) viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.043

Generation of influenza A viruses entirely from cloned cDNAs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.043

Protection against tetanus by needle-free inoculation of adenovirus-vectored nasal and epicutaneous vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.043

Induction of protective immunity by topic application of a recombinant adenovirus expressing rabies virus glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.043

Enabling topical immunization via microporation: a novel method for pain-free and needle-free delivery of adenovirus-based vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.043

Examination of parameters affecting the elicitation of humoral immune responses by particle bombardment-mediated genetic immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.043

Analytical anion-exchange HPLC of recombinant type-5 adenoviral particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.043

Overexpression of adenovirus-encoded transgenes from the cytomegalovirus immediate early promoter in irradiated tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.043

Nucleotide sequence of the haemagglutinin gene of a human influenza virus H1 subtype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.043

AdEasy system made easier by selecting the viral backbone plasmid preceding homologous recombination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.043

A single short stretch of homology between adenoviral vector and packaging cell line can give rise to cytopathic effect-inducing, helper-dependent E1-positive particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.043

Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.043

Evaluation of a single dose of half strength inactivated influenza vaccine in healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.043

Sequence of an influenza virus hemagglutinin determined directly from a clinical sample

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.043

Large-scale propagation of a replication-defective adenovirus vector in stirred-tank bioreactor PER.C6 cell culture under sparging conditions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.043

Development and optimization of an adenovirus production process

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.043

Intranasal immunization with inactivated influenza vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.043

Incidence and prevalence of neutralizing antibodies to the common adenoviruses in children with cystic fibrosis: implication for gene therapy with adenovirus vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.043

A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.043

A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin-specific antibodies that display very low virus-neutralizing activity in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.043

10.1016/J.VACCINE.2004.07.043

7 January 2021

Identifiers

DOI

1 reference

20 September 2017

1 reference